Publication:
The State of Melanoma: Emergent Challenges and Opportunities.

dc.contributor.authorAtkins, Michael B
dc.contributor.authorCuriel-Lewandrowski, Clara
dc.contributor.authorFisher, David E
dc.contributor.authorSwetter, Susan M
dc.contributor.authorTsao, Hensin
dc.contributor.authorAguirre-Ghiso, Julio A
dc.contributor.authorSoengas, Maria S
dc.contributor.authorWeeraratna, Ashani T
dc.contributor.authorFlaherty, Keith T
dc.contributor.authorHerlyn, Meenhard
dc.contributor.authorSosman, Jeffrey A
dc.contributor.authorTawbi, Hussein A
dc.contributor.authorPavlick, Anna C
dc.contributor.authorCassidy, Pamela B
dc.contributor.authorChandra, Sunandana
dc.contributor.authorChapman, Paul B
dc.contributor.authorDaud, Adil
dc.contributor.authorEroglu, Zeynep
dc.contributor.authorFerris, Laura K
dc.contributor.authorFox, Bernard A
dc.contributor.authorGershenwald, Jeffrey E
dc.contributor.authorGibney, Geoffrey T
dc.contributor.authorGrossman, Douglas
dc.contributor.authorHanks, Brent A
dc.contributor.authorHanniford, Douglas
dc.contributor.authorHernando, Eva
dc.contributor.authorJeter, Joanne M
dc.contributor.authorJohnson, Douglas B
dc.contributor.authorKhleif, Samir N
dc.contributor.authorKirkwood, John M
dc.contributor.authorLeachman, Sancy A
dc.contributor.authorMays, Darren
dc.contributor.authorNelson, Kelly C
dc.contributor.authorSondak, Vernon K
dc.contributor.authorSullivan, Ryan J
dc.contributor.authorMerlino, Glenn
dc.contributor.authorSoengas, MS
dc.contributor.funderNational Institutes of Health (Estados Unidos)
dc.contributor.funderMelanoma Research Foundation
dc.contributor.funderInterMEL
dc.contributor.funderMichael and Patricia Booker Melanoma Research Endowment
dc.contributor.funderRobert and Lynne Grossman Family Foundation
dc.date.accessioned2024-10-29T09:54:53Z
dc.date.available2024-10-29T09:54:53Z
dc.date.issued2021-05-15
dc.descriptionThe authors are indebted to Dr. Robyn Burns, Science Officer for the Melanoma Research Foundation, for her expert assistance with the preparation of this article. Research reported in this publication was supported, in part, by the NIH SPORE grants (1P50CA221703 to J.E. Gershenwald and P50CA225450 to E. Hernando), DoD/CDMRP Team Science Award (CA170374 to J.E. Gershenwald), the Robert and Lynne Grossman Family Foundation (to J.E. Gershenwald), the Michael and Patricia Booker Melanoma Research Endowment (to J.E. Gershenwald), philanthropic contributions to the Melanoma Moon Shots Program ofMDAnderson (to J.E. Gershenwald), NIH intramural research program (ZIABC008756 to G. Merlino), the InterMEL P01 (P01CA206980 to E. Hernando), and the Melanoma Research Foundation.
dc.description.abstractFive years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma. Since then, remarkable progress has been made on both the basic and clinical research fronts. However, the incidence, recurrence, and death rates for melanoma remain unacceptably high and significant challenges remain. Hence, the MRF Scientific Advisory Council and Breakthrough Consortium, a group that includes clinicians and scientists, reconvened to facilitate intensive discussions on thematic areas essential to melanoma researchers and patients alike, prevention, detection, diagnosis, metastatic dormancy and progression, response and resistance to targeted and immune-based therapy, and the clinical consequences of COVID-19 for patients with melanoma and providers. These extensive discussions helped to crystalize our understanding of the challenges and opportunities facing the broader melanoma community today. In this report, we discuss the progress made since the last MRF assessment, comment on what remains to be overcome, and offer recommendations for the best path forward.
dc.description.peerreviewed
dc.format.number10
dc.format.page2678-2697
dc.format.volume27
dc.identifier.citationClin Cancer Res . 2021 May 15;27(10):2678-2697
dc.identifier.pmchttps://pmc.ncbi.nlm.nih.gov/articles/PMC8127340/pdf/nihms-1659932.pdf
dc.identifier.pubmedID33414132
dc.identifier.urihttps://hdl.handle.net/20.500.12105/25363
dc.language.isoeng
dc.publisherAmerican Association for Cancer Research (AACR)
dc.relation.publisherversionhttp://www. 10.1158/1078-0432.CCR-20-4092
dc.repisalud.institucionCNIO
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Melanoma
dc.rights.accessRightsopen access
dc.rights.licenseAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectTARGETED THERAPY
dc.subjectSYSTEMIC THERAPY
dc.subjectIMMUNOTHERAPY
dc.subjectRECOMMENDATIONS
dc.subjectASSOCIATION
dc.subjectMORTALITY
dc.subjectSUNBURN
dc.subjectTUMOR
dc.titleThe State of Melanoma: Emergent Challenges and Opportunities.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication1e509973-403a-4c27-84e4-e6e660f67f68
relation.isAuthorOfPublication.latestForDiscovery1e509973-403a-4c27-84e4-e6e660f67f68
relation.isFunderOfPublicationd863b318-3e6b-4cfc-81bb-a6d112b1f86e
relation.isFunderOfPublication.latestForDiscoveryd863b318-3e6b-4cfc-81bb-a6d112b1f86e
relation.isPublisherOfPublicationfeeb2648-1129-4dba-838d-68d8d9be6f57
relation.isPublisherOfPublication.latestForDiscoveryfeeb2648-1129-4dba-838d-68d8d9be6f57

Files